← Back to catalogue

CD62L-PE-Vio770

FDA UDI

Class I (US FDA UDI)

by Miltenyi Biotec B.V. & Co. KG

Identity

Trade Name
CD62L-PE-Vio770 FDA UDI
Generic Name
Assay development analyte-specific reagent IVD FDA UDI
Device Name
145/15 recognizes the human CD62L antigen, a 74 kDa glycoprotein and a member of the selectin family of cell surface molecules. CD62L is also known as L-selectin, LECAM-1, or LAM-1 and binds a series of glycoproteins including CD34, GlyCAM-1, and MAdCAM-1. CD62L is important for homing of naive lymphocytes via endothelial venules to peripheral lymph nodes and Peyer’s patches. The CD62L antigen also contributes to the recruitment of leukocytes from the blood to areas of inflammation. Most hematopoietic cells express CD62L, including many peripheral blood B cells, T cells, monocytes, granulocytes, and some myeloid cells from bone marrow, and thymocytes. CD62L is continuously endoproteolytically cleaved from the cell surface neutrophils and lymphocytes (shedding). Proteolysis is accelerated, for example, after antigenic activation of T cells. Always use fresh material for immunofluorescent staining of CD62L+ cells. For optimal results, the cells should not be older than 8–12 hours. Keep cells continuously cold. CD62L-expression may be rapidly lost due to shedding. FDA UDI
Model / Reference
170-081-082 FDA UDI
Description
145/15 recognizes the human CD62L antigen, a 74 kDa glycoprotein and a member of the selectin family of cell surface molecules. CD62L is also known as L-selectin, LECAM-1, or LAM-1 and binds a series of glycoproteins including CD34, GlyCAM-1, and MAdCAM-1. CD62L is important for homing of naive lymphocytes via endothelial venules to peripheral lymph nodes and Peyer’s patches. The CD62L antigen also contributes to the recruitment of leukocytes from the blood to areas of inflammation. Most hematopoietic cells express CD62L, including many peripheral blood B cells, T cells, monocytes, granulocytes, and some myeloid cells from bone marrow, and thymocytes. CD62L is continuously endoproteolytically cleaved from the cell surface neutrophils and lymphocytes (shedding). Proteolysis is accelerated, for example, after antigenic activation of T cells. Always use fresh material for immunofluorescent staining of CD62L+ cells. For optimal results, the cells should not be older than 8–12 hours. Keep cells continuously cold. CD62L-expression may be rapidly lost due to shedding. FDA UDI

Identifiers

Primary DI / UDI-DI
04049934133770 FDA UDI
FDA Product Code
MVU FDA UDI
GMDN Term
Assay development analyte-specific reagent IVD FDA UDI

Classification

Device Class
Class I FDA UDI
Regulation Number
864.4020 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

No

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

Yes

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

Yes

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

Yes

FDA UDI

Category: Assay development analyte-specific reagent IVD

CD62L-PE-Vio770 by Miltenyi Biotec B.V. & Co. KG — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Assay development analyte-specific reagent IVD.

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Miltenyi Biotec B.V. & Co. KG

Sources (1)

  • FDA UDI aa1921a3-a49f-4a72-bf32-78dd304f8507 35 fields · synced Jun 8, 2026